全文获取类型
收费全文 | 5344篇 |
免费 | 445篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 116篇 |
妇产科学 | 87篇 |
基础医学 | 602篇 |
口腔科学 | 121篇 |
临床医学 | 504篇 |
内科学 | 702篇 |
皮肤病学 | 34篇 |
神经病学 | 404篇 |
特种医学 | 195篇 |
外科学 | 388篇 |
综合类 | 421篇 |
一般理论 | 1篇 |
预防医学 | 1044篇 |
眼科学 | 62篇 |
药学 | 449篇 |
中国医学 | 168篇 |
肿瘤学 | 501篇 |
出版年
2023年 | 119篇 |
2022年 | 139篇 |
2021年 | 228篇 |
2020年 | 253篇 |
2019年 | 189篇 |
2018年 | 218篇 |
2017年 | 194篇 |
2016年 | 192篇 |
2015年 | 201篇 |
2014年 | 357篇 |
2013年 | 428篇 |
2012年 | 307篇 |
2011年 | 328篇 |
2010年 | 254篇 |
2009年 | 269篇 |
2008年 | 254篇 |
2007年 | 255篇 |
2006年 | 198篇 |
2005年 | 187篇 |
2004年 | 132篇 |
2003年 | 134篇 |
2002年 | 89篇 |
2001年 | 91篇 |
2000年 | 79篇 |
1999年 | 69篇 |
1998年 | 62篇 |
1997年 | 52篇 |
1996年 | 39篇 |
1995年 | 37篇 |
1994年 | 45篇 |
1993年 | 32篇 |
1992年 | 32篇 |
1991年 | 29篇 |
1990年 | 21篇 |
1989年 | 31篇 |
1988年 | 28篇 |
1987年 | 18篇 |
1986年 | 13篇 |
1985年 | 25篇 |
1984年 | 27篇 |
1983年 | 13篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1978年 | 14篇 |
1976年 | 13篇 |
1975年 | 22篇 |
1974年 | 14篇 |
1972年 | 12篇 |
排序方式: 共有5845条查询结果,搜索用时 15 毫秒
1.
[摘要] 目的 对发热伴血小板减少综合征(severe fever with thrombocytopenia syndrome, SFTS)的相关文献进行文献计量学和可视化分析,探寻近年来的研究现状、热点及趋势,为临床治疗和基础研究提供参考。方法?以Web of Science(WOS)核心合集和中国知网(China national knowledge infrastructure, CNKI)数据库为文献来源,检索2011年1月1日—2021年12月31日有关SFTS的文献,导入CiteSpace.5.7.R2软件,以国家、作者、文献共被引、关键词为节点进行可视化分析,并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献,在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势,中国发文量居首位,美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟,新型布尼亚病毒、免疫功能、预后是研究重点,但是对SFTS发病机制和病毒受体尚不清楚,仍须进一步探索。 相似文献
2.
地鳖中的纤溶活性蛋白是从地鳖中提取的具有抗栓及抗肿瘤作用的有效成分,其口服易被上消化道酶分解从而限制了应用。采用恒流泵滴制法开发地鳖纤溶活性蛋白时间/pH依赖口服结肠靶向微囊(EnpolypHaga fibrinolytic protein oral colon targeting microcapsules, CTM-EFP)。采用单因素实验和正交实验相结合的方法寻找到包封率为60.17 % ± 2.72 %、载药量为15.50 % ± 0.44 % 的最佳配方。扫描电子显微镜(SEM)显示微囊呈球形、表面光滑,在人工肠液中24 h的累积释放度为99.53 % ± 0.69 %,在人工胃液中24 h累积释放度为7.43 ± 1.04 %,通过时间/pH依赖达到结肠靶向作用。CTM-EFP在人工肠液中的体外释放曲线符合Korsmeyer方程,提示地鳖纤溶活性蛋白(EnpolypHaga fibrinolytic protein, EFP)是通过扩散和侵蚀机制结合释放的。CTM-EFP为EFP的口服给药提供了一种新的剂型,为EFP应用于临床提供参考。 相似文献
3.
ObjectivesTo examine the impact of time to surgery (TTS) on survival among patients with stage I non-small cell lung cancer (NSCLC).MethodsAll patients in the Canadian province of Ontario with stage I NSCLC from 2007 to 2017 were included. A logistic regression identified the predictors of TTS and a flexible parametric model estimated survival rates based on TTS.ResultsOver the study period, 6428 patients with stage I NSCLC undergoing surgical resection were identified, of which 62.5% had TTS >28 days. Less than half these patients (40.8%) underwent open resection, with 19.3% undergoing open sublobar and 21.5% undergoing open lobectomy. Adenocarcinoma and squamous cell carcinoma tumors accounted for 33.3% and 22.0% of cases, respectively. The majority (85.6%) of patients lived in urban areas within 50 km of a regional cancer center (76.9%). Variables that predicted TTS >28 days include age and extent of resection. After adjustment for VATS vs. open resection, age, sex, frailty, year of diagnosis, histology of tumor, and extent of resection, the hazard ratio for TTS >28 days was 1.26 (95%CI:1.13–1.40), indicating a 26% increased risk of all-cause mortality (p < 0.0001). The highest 5-year survival was observed for patients with stage I disease undergoing resection within 28 days.ConclusionsThe present study found age and extent of resection to be associated with increased TTS. Importantly, patients with TTS >28 days had reduced long-term survival. 相似文献
4.
5.
Lina Jansen Lars Schwettmann Christian Behr Andrea Eberle Bernd Holleczek Christina Justenhoven Hiltraud Kajüter Kirsi Manz Frederik Peters Ron Pritzkuleit Andrea Schmidt-Pokrzywniak Eunice Sirri Fabian Tetzlaff Sven Voigtländer Volker Arndt 《International journal of cancer. Journal international du cancer》2023,153(10):1784-1796
Age-standardized cancer incidence has decreased over the last years for many cancer sites in developed countries. Whether these trends led to narrowing or widening socioeconomic inequalities in cancer incidence is unknown. Using cancer registry data covering 48 million inhabitants in Germany, the ecological association between age-standardized total and site specific (colorectal, lung, prostate and breast) cancer incidence in 2007 to 2018 and a deprivation index on district level (aggregated to quintiles) was investigated. Incidence in the most and least deprived districts were compared using Poisson models. Average annual percentage changes (AAPCs) and differences in AAPCs between deprivation quintiles were assessed using Joinpoint regression analyses. Age-standardized incidence decreased strongly between 2007 and 2018 for total cancer and all cancer sites (except female lung cancer), irrespective of the level of deprivation. However, differences in the magnitude of trends across deprivation quintiles resulted in increasing inequalities over time for total cancer, colorectal and lung cancer. For total cancer, the incidence rate ratio between the most and least deprived quintile increased from 1.07 (95% confidence interval: 1.01-1.12) to 1.23 (1.12-1.32) in men and from 1.07 (1.01-1.13) to 1.20 (1.14-1.26) in women. Largest inequalities were observed for lung cancer with 82% (men) and 88% (women) higher incidence in the most vs the least deprived regions in 2018. The observed increase in inequalities in cancer incidence is in alignment with trends in inequalities in risk factor prevalence and partly utilization of screening. Intervention programs targeted at socioeconomically deprived and urban regions are highly needed. 相似文献
6.
背景 随着血糖监测技术的发展,近些年来人们开始使用扫描式葡萄糖监测系统(FGMS)"全景式"地观察2型糖尿病(T2DM)患者的血糖水平,明确FGMS指标与T2DM并发症之间的关系有助于提高其临床应用价值,但目前相关研究较少。 目的 探究佩戴FGMS的T2DM患者葡萄糖在目标范围内时间(TIR)等指标与尿白蛋白/肌酐比值(UACR)的相关性。 方法 选取2019年1月至2021年10月于北京大学人民医院老年科就诊并佩戴FGMS的T2DM患者79例,以尿液检查中UACR是否<30 mg/g将患者分为无白蛋白尿组(n=50)和白蛋白尿组(n=29)。比较两组患者的临床特征、实验室检查指标及FGMS指标等。采用Pearson相关、Spearman秩相关分析探讨TIR、高血糖时间(TAR)与糖化血红蛋白(HbA1c)的相关性。分别采用Pearson相关、Spearman秩相关、偏相关分析探讨FGMS指标与lnUACR的相关性。使用多因素Logistic回归分析探究T2DM患者发生白蛋白尿的影响因素,采用受试者工作特征(ROC)曲线评估TIR对白蛋白尿的预测价值。 结果 白蛋白尿组T2DM病程长于无白蛋白尿组,三酰甘油(TG)、HbA1c、平均血糖(MBG)、TAR、平均血糖标准差(SDBG)、最大葡萄糖波动幅度(LAGE)、平均葡萄糖波动幅度(MAGE)、连续每隔2 h血糖净作用(CONGA2)高于无白蛋白尿组,TIR低于无白蛋白尿组(P<0.05)。Pearson相关、Spearman秩相关分析结果显示,TIR与HbA1c呈负相关(P<0.001),TAR与HbA1c呈正相关(P<0.001)。Pearson相关、Spearman秩相关、偏相关分析结果均表明,TIR与lnUACR呈负相关(P<0.001),MBG、TAR、SDBG、LAGE、MAGE、CONGA2与lnUACR呈正相关(P<0.001)。多因素Logistic回归分析结果显示,TIR>70%〔OR=0.038,95%CI(0.003,0.467)〕是T2DM患者出现白蛋白尿的保护因素(P<0.05),TAR升高〔OR=1.046,95%CI(1.000,1.094)〕是T2DM患者出现白蛋白尿的危险因素(P<0.05)。TIR预测T2DM患者出现白蛋白尿的ROC曲线下面积(AUC)为0.784〔95%CI(0.674,0.894)〕(P=0.003),灵敏度为78%,特异度为83%,最佳切点为69.71%。 结论 在FGMS指标中,TIR>70%是T2DM患者出现白蛋白尿的保护因素,TAR升高是T2DM患者出现白蛋白尿的危险因素。同时,SDBG、LAGE、MAGE、CONGA2等多种反映血糖波动的指标也与UACR密切相关。对TIR水平较低及TAR、SDBG、LAGE、MAGE、CONGA2水平较高的T2DM患者进行FGMS筛查有助于早期识别及预防白蛋白尿的发生、发展。 相似文献
7.
[摘要] 目的 对发热伴血小板减少综合征(severe fever with thrombocytopenia syndrome, SFTS)的相关文献进行文献计量学和可视化分析,探寻近年来的研究现状、热点及趋势,为临床治疗和基础研究提供参考。方法?以Web of Science(WOS)核心合集和中国知网(China national knowledge infrastructure, CNKI)数据库为文献来源,检索2011年1月1日—2021年12月31日有关SFTS的文献,导入CiteSpace.5.7.R2软件,以国家、作者、文献共被引、关键词为节点进行可视化分析,并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献,在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势,中国发文量居首位,美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟,新型布尼亚病毒、免疫功能、预后是研究重点,但是对SFTS发病机制和病毒受体尚不清楚,仍须进一步探索。 相似文献
8.
9.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
10.